MDB Capital Upgrades Maxygen (MAXY) to Buy
Tweet Send to a FriendGet Alerts MAXY Hot Sheet
Price: $2.49 -0.4%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade MAXY Now!
MDB Capital upgrades and reinstates its coverage on Maxygen (Nasdaq: MAXY) with a Buy rating and a $15 price target.
The firm said it is optimistic about the potential of MAXY-G34 and Maxygen's protein optimization pipeline and technology platform. Furthermore, MDB said that the Street is currently undervaluing Maxygen's stake in Codexis.
Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions.
The firm said it is optimistic about the potential of MAXY-G34 and Maxygen's protein optimization pipeline and technology platform. Furthermore, MDB said that the Street is currently undervaluing Maxygen's stake in Codexis.
Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions.
You May Also Be Interested In
- UPDATE: BofA/Merrill Lynch Upgrades Adobe (ADBE) to Buy
- Piper Jaffray Upgrades United Natural Foods (UNFI) to Overweight
- UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
Create E-mail Alert Related Categories
Upgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
